Antipodean Pharmaceuticals Initiates Phase 2 Trial In Hepatitis C

Tue, 06 Feb 2007 02:00 PM EST

... Antipodean Pharmaceuticals, Inc. today announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV). The principal investigator for the trial, Dr. [click link for full article] ...